Overview

Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety at 48 weeks between LPV/r monotherapy and 2 NRTIs + LPV/r therapy in patients failing a standard NNRTI-based treatment regimen. Also, to evaluate the short-term 24-week efficacy and safety of Lopinavir/ritonavir (LPV/r) monotherapy and 2 NRTIs+LPV/r therapy in patients failing a standard NNRTI-based treatment regimen as an interim analyses when 50% of the patients in each arm have reached 24 weeks after randomization. Last, to define risk factors for monotherapy failure in HIV-treated individuals Hypothesis. The rate of virologic suppression is not inferior in the monotherapy arm.

Phase:

Phase 4

Details

Lead Sponsor:

The HIV Netherlands Australia Thailand Research Collaboration

Collaborators:

National Health Security Office, Thailand
Swiss HIV Cohort Study

Treatments:

Reverse Transcriptase Inhibitors